Alexion Pharmaceuticals, Inc. (ALXN)
(Delayed Data from NSDQ)
$136.69 USD
+3.56 (2.67%)
Updated May 3, 2019 04:00 PM ET
After-Market: $136.70 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$136.69 USD
+3.56 (2.67%)
Updated May 3, 2019 04:00 PM ET
After-Market: $136.70 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU
by Zacks Equity Research
The European Commission confers an orphan drug status on Dicerna's (DRNA) RNAi therapeutic DCR-A1AT for the treatment of congenital alpha-1 antitrypsin (A1AT) deficiency.
Alexion Pharmaceuticals (ALXN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) closed the most recent trading day at $109.82, moving -1.39% from the previous trading session.
3 Reasons Why Alexion (ALXN) Is a Great Growth Stock
by Zacks Equity Research
Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.
Top Ranked Growth Stocks to Buy for December 16th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, December 16th
6 Low Price-to-Book Value Stocks to Buy in December
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks with high-growth prospects.
Zacks.com featured highlights include: Quanta Services, Alexion Pharmaceuticals, Jazz Pharmaceuticals and Changyou.com
by Zacks Equity Research
Zacks.com featured highlights include: Quanta Services, Alexion Pharmaceuticals, Jazz Pharmaceuticals and Changyou.com
Alexion (ALXN) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
Alexion (ALXN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Create a Standout Portfolio With These 4 Low P/CF Stocks
by Sumit Singh
Investing in stocks based on value analysis is generally considered one of the best practices. In value investing, investors pick stocks that are usually cheap but fundamentally sound.
Zacks.com featured highlights include: Alexion Pharmaceuticals, OpGen, Integer, ReWalk Robotics and Civeo
by Zacks Equity Research
Zacks.com featured highlights include: Alexion Pharmaceuticals, OpGen, Integer, ReWalk Robotics and Civeo
5 Discounted PEG Stocks for GARP Investors
by Urmimala Biswas
Although PEG is categorized under value investing, it follows the principles of both growth and value investing.
Adopt Rising P/E Technique With These 5 Top-Ranked Stocks
by Sanghamitra Saha
What bargain hunting? Stocks with a rising P/E can also be worth buying too.
ALXN vs. ILMN: Which Stock Is the Better Value Option?
by Zacks Equity Research
ALXN vs. ILMN: Which Stock Is the Better Value Option?
Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates.
The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion
4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal
by Kinjel Shah
Here are four stocks that boast promising prospects and are most likely to be takeout targets.
Alexion Gets Approval for Label Expansion of Soliris in Japan
by Zacks Equity Research
Alexion (ALXN) gets Japan Ministry of Health, Labour and Welfare's approval for the label expansion of Soliris.
Alexion (ALXN) Up 3.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Alexion (ALXN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals
Achillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNH
by Zacks Equity Research
Achillion's (ACHN) lead pipeline candidate danicopan receives PRIME status from the EMA as a treatment option for PNH in patients, who are not adequately responding to a C5 inhibitor.
4 Big Biotech Stocks Worth Considering Post Q3 Earnings
by Zacks Equity Research
We highlight a few principal players from the biotech sector, which are likely to witness a winning run in the near term.
ALXN vs. CBM: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ALXN vs. CBM: Which Stock Is the Better Value Option?
Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys
by Zacks Equity Research
Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys
What Bargain Hunting? Tap 5 Stocks With Rising P/E
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E for outsized gains.
The Zacks Analyst Blog Highlights: AMETEK, Thermo Fisher Scientific, IQVIA, Lowe's Companies and Alexion Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AMETEK, Thermo Fisher Scientific, IQVIA, Lowe's Companies and Alexion Pharmaceuticals
Alexion (ALXN) Up 10 % YTD on Soliris & Ultomiris Strength
by Zacks Equity Research
Alexion's (ALXN) stock rises 10% in the year so far as Soliris maintains momentum and Ultomiris gains further traction.